Frank Verwiel served as President, Chief Executive Officer and a board member of Aptalis Pharma, Inc., a privately-held, specialty pharmaceutical company, which was acquired by Forest Laboratories, Inc. (now Allergan Inc.) in 2014. Previously, Frank held international senior management positions with Merck & Co., Inc. and Servier Laboratories SA.
Frank serves as a board member of Achillion Inc., Bavarian Nordic A/S and Intellia Inc. He was a board member of InterMune, Inc. until it was acquired by Roche in 2014 and Avexis Inc. until it was acquired by Novartis in 2018.. Frank was also a board member of the Biotechnology Industry Organisation (BIO).
Frank holds an MD from Erasmus University, Rotterdam in The Netherlands and an MBA from INSEAD, Fontainebleau in France.